The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside [Corrigendum]

Rovero P, Malgapo DMH, Sparavigna A, Beilin G, Wong V, Lao MP. Clin Cosmet Investig Dermatol. 2022;15:2693–2703.

The authors have advised that there is an error in the Study characteristics for Face serum (ISPE, 2022) in Table 2 on page 2698. The correct Table 2 is as follows.

Table 2.

Results of Instrumental and Subjective Evaluations of SA1-III Face Cream and Face Serum

Product	Face Cream (ISPE, 2018)25	Face Serum (ISPE, 2022)26
Study characteristics	Included 20 female volunteers aged 40 to 70 years (average age of 60.0 years) All volunteers applied KP1 face cream twice daily for 4 weeks)	Included 20 female and 10 male volunteers All volunteers applied KP1 face serum
Results (baseline vs end of study)
Skin hydration (cu)	52.2 ± 5.3 vs 74.7 ± 8.2 (Δ22.5; 43.1%; p<0.0001)	52.5 ± 9.6 vs 69.3 ± 11.0 (Δ16.8; 32.0%; p<0.0001)
Skin deep hydration (%)	NR	49.9 ± 5.1 vs 53.2 ± 4.0 (3.3; p<0.01)
Skin extensibility (mm)	0.230 ± 0.056 vs 0.197 ± 0.058 (Δ−0.033; −14.3%; p<0.0001)	0.296 ± 0.084 vs 0.212 ± 0.084 (Δ−0.084; −28.4%; p<0.0001)
Gross elasticity	0.591 ± 0.066 vs 0.625 ± 0.063 (Δ0.034; 5.8%; p<0.0001)	0.668 ± 0.110 vs 0.726 ± 0.103 (Δ0.058; 8.7%; p<0.0001)
Skin echogenicity/density (%)	31.54 ± 6.04 vs 33.77 ± 5.22 (2.23; p<0.001)	30.15 ± 6.53 vs 32.82 ± 6.81 (Δ2.67; p<0.0001)
Average skin roughness (μm)	66.4 ± 4.4 vs 58.8 ±15.3 (Δ−8.6; −13.0%; p<0.01)	46.2 ± 12.2 vs 40.0 ± 8.8 (Δ−6.2; −13.4%; p<0.001)
Average maximum roughness (μm)	849 ± 145 vs 763 ± 193 (−86; −10.1%; p<0.001)	540.1 ± 123.2 vs 462.7 ± 114.4 (−77.4; −14.3%; p<0.001)

The authors apologise for this error.